Equities research analysts at William Blair decreased their FY2026 earnings per share estimates for shares of Bristol-Myers ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

Top stock picks for capital appreciation and outperformance, with a focus on profits, dividends, and long-term viability. Click for more on Capital Appreciation.

Shares of The Bristol-Myers Squibb Company (NYSE: BMY)are attempting to claw their way back into positive territory after the ...

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks.

Drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a share-price ...

Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid ...

The company forecast 2025 revenue of around $45.5 billion, down from $48.3 billion in 2024 and below analyst expectations of $47.4 billion, according to LSEG data. It forecast 2025 earnings in the ...

The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...